Rapport Therapeutics Inc.... (RAPP)
13.38
0.69 (5.44%)
At close: Jan 15, 2025, 10:32 AM
Company Description
No Company description available at the moment.
Rapport Therapeutics Inc. Common Stock
| Country | n/a |
| IPO Date | n/a |
| Industry | n/a |
| Sector | n/a |
| Employees | 58 |
| CEO | Abraham N. Ceesay M.B.A. |
Contact Details
Address: No Address available No city data available, | |
| Website | n/a |
Stock Details
| Ticker Symbol | RAPP |
| Exchange | NASDAQ |
| Fiscal Year | n/a |
| Reporting Currency | n/a |
| CIK Code | 0002012593 |
| CUSIP Number | n/a |
| ISIN Number | US75383L1026 |
| Employer ID | 88-0724208 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Abraham N. Ceesay M.B.A. | Chief Executive Officer, President, Treasurer & Director |
| Cheryl Gault | Chief Operating Officer |
| Dr. Troy A. Ignelzi | Chief Financial Officer |
| Karina Chmielewski | Chief Information Officer & Head of Operations |
| Kathleen A. Wilkinson | Chief People Officer |
| David Bredt M.D., Ph.D. | Founder & Chief Scientific Officer |
| Dr. Arnold R. Gammaitoni Pharm.D. | Senior Vice President of Medical Affairs |
| Dr. Steven M. Paul M.D. | Founder & Independent Chairman |
| Julie DiCarlo | Head of Communications & Investor Relations |
| Swamy Yeleswaram Ph.D. | Chief Development Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 10, 2025 | 8-K | Current Report |
| Nov 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 13, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 07, 2024 | 4 | Filing |
| Nov 07, 2024 | 4 | Filing |
| Nov 07, 2024 | 4 | Filing |
| Nov 07, 2024 | 4 | Filing |
| Nov 07, 2024 | 3 | Filing |